中国药物警戒 ›› 2021, Vol. 18 ›› Issue (8): 731-736.
DOI: 10.19803/j.1672-8629.2021.08.07

• 新型抗肿瘤药物利用、风险性与经济性研究专栏 • 上一篇    下一篇

基于终端数据的南京地区抗肿瘤新药市场竞争趋势分析

王晓1, 何璇1, 戴惠珍2, 李歆1,3,4,*, 韩峰3#   

  1. 1南京医科大学医政学院,江苏 南京 211166;
    2江苏省医药情报研究所,江苏 南京 210000;
    3南京医科大学药学院,江苏 南京211166;
    4南京医科大学全球健康中心,江苏 南京 211166
  • 收稿日期:2021-03-25 出版日期:2021-08-15 发布日期:2021-08-17
  • 通讯作者: *李歆,男,博士,教授·博导,临床药学与药物政策。E-mail:xinli@njmu.edu.cn #为共同通信作者。
  • 作者简介:王晓,女,硕士,公共管理与药事管理。
  • 基金资助:
    国家自然科学基金资助项目 (72074123,716731471); 江苏省政策引导类计划 (软科学研究) (BR2020043)

Market Competition Trends of Innovative Anti-tumor Drugs in Nanjing Based on Terminal Data

WANG Xiao1, HE Xuan1, DAI Huizhen2, LI Xin1,3,4,*, HAN Feng3#   

  1. 1School of Health Policy and Management, Nanjing Medical University, Nanjing Jiangsu 211166, China;
    2Jiangsu Medicine Information Institute, Nanjing Jiangsu 210000, China;
    3School of Pharmacy, Nanjing Medical University, Nanjing Jiangsu 211166, China;
    4Center for Global Health, Nanjing Medical University, Nanjing Jiangsu 211166, China
  • Received:2021-03-25 Online:2021-08-15 Published:2021-08-17

PDF (PC)

85

摘要： 目的 分析评价南京地区抗肿瘤新药市场竞争现状及发展趋势,为进一步提升我国医药产业的竞争力提出针对性的对策。方法 通过南京地区35家二级和三级医院2016年~ 2019年抗肿瘤新药采购数据,分析抗肿瘤新药类型、品种、销售金额、市场份额以及国内厂家与进口厂家药品的销售分布情况。结果 抗肿瘤新药销售金额年平均增长率为41.27%,细胞毒药物约占60%市场份额,分子靶向药物中单克隆抗体和多靶点酪氨酸激酶抑制剂增长速度快,抗肿瘤新药占总销售金额约20%,国产抗肿瘤新药约占60%。结论 南京地区抗肿瘤新药终端市场销售金额呈增长趋势,靶向药物市场空间大、与细胞毒类联合用药成趋势,与进口企业相比国企创新能力待提高。

关键词: 抗肿瘤新药, 销售金额, 市场竞争, 趋势分析

Abstract: Objective To analyze and evaluate the current market competition and developments of new anti-tumor drugs in Nanjing, and recommend countermeasures to enhance the competitiveness of China's pharmaceutical industry. Methods Based on the statistics of the consumption of innovative anti-tumor drugs used in 35 secondary and tertiary hospitals in Nanjing between 2016 and 2019, the types, varieties, sales amount, market share of innovative anti-tumor drugs and the sales distribution of medicines produced by domestic or overseas manufacturers were analyzed. Results The sales amount of new anti-tumor drugs increased at an annual average rate of 41.27%. Cytotoxic drugs held almost 60% of the market share of innovative anti-tumor drugs. Among molecular targeted drugs, monoclonal antibodies and multi-target tyrosine kinase inhibitors were growing rapidly. New anti-tumor drugs accounted for about 20% of the total sales amount, and home-made new anti-tumor drugs accounted for about 60%. Conclusion The sales amount of innovative anti-tumor drugs in the terminal market in Nanjing is trending up. Targeted drugs have a large market space and tend to be used in combination with cytotoxic drugs. Compared with import enterprises, state-owned enterprises need to improve their ability to make innovations. enterprises, state-owned enterprises need to improve their ability to make innovations.

Key words: anti-tumor innovative drugs, sales amount, market competition, trend analysis

中图分类号: